Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Kisspeptin's Mechanism: GPR54 Activation vs GH Secretagogue Pathways

Kisspeptin-10, the most researched fragment, is a 10-amino-acid peptide derived from the KISS1 gene. It binds to GPR54 (also called KISS1R), a G-protein-coupled receptor expressed densely in the hypothalamus. This binding triggers intracellular calcium release

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Kisspeptin-10, the most researched fragment, is a 10-amino-acid peptide derived from the KISS1 gene. It binds to GPR54 (also called KISS1R), a G-protein-coupled receptor expressed densely in the hypothalamus. This binding triggers intracellular calcium release and activates phospholipase C signaling, which stimulates GnRH neurons to release gonadotropin-releasing hormone in pulsatile bursts. GnRH then travels to the anterior pituitary, where it binds to GnRH receptors and stimulates the release of LH and FSH. The hormones that directly regulate gonadal function in both sexes.
  • This is mechanistically distinct from growth hormone secretagogues. Peptides like GHRP-2 and MK-677 act as ghrelin receptor agonists, binding to growth hormone secretagogue receptors (GHS-R1a) in the pituitary and hypothalamus. This binding increases intracellular calcium concentration in somatotroph cells, leading to pulsatile GH release. The elevated GH then stimulates hepatic IGF-1 synthesis, which drives anabolic processes. Muscle protein synthesis, lipolysis, and bone remodeling. Kisspeptin does not interact with GHS-R1a receptors at all.
  • A 2016 paper in The Journal of Clinical Endocrinology & Metabolism demonstrated that kisspeptin-10 administration in healthy men increased LH and testosterone levels within 90 minutes, with no detectable change in GH or IGF-1 concentrations. Conversely, GHRP-2 administration in the same study elevated GH by 5–8-fold within 30 minutes but had no effect on LH secretion. The pathways are parallel, not overlapping.